Literature DB >> 18410226

Significance of serum TRACP in rheumatoid arthritis.

Anthony J Janckila1, David H Neustadt, Lung T Yam.   

Abstract

Human serum contains two related isoforms of TRACP: TRACP 5a and TRACP 5b. Serum TRACP 5a protein is increased in about one third of rheumatoid arthritis (RA) sera. This study was undertaken to examine the significance of serum TRACP isoforms 5a and 5b as disease markers of inflammation and bone destruction in RA. One hundred eighteen patients were recruited including 50 with RA (25 with nodules), 26 with osteoarthritis (OA), and 42 with other rheumatic diseases. Twenty-six healthy adults served as controls. Serum TRACP 5a activity, TRACP 5a protein, and TRACP 5b activity were determined by in-house immunoassays. C-reactive protein (CRP) was determined by in-house immunoassay using commercial antibodies and CRP. Other commercial markers included bone-specific alkaline phosphatase (BALP), C-telopeptides of type-I collagen (ICTP), cartilage glycoprotein-39 (YKL-40), and IgM rheumatoid factors (IgM-RF). Mean TRACP 5a protein was significantly elevated only in RA compared with healthy controls and other disease groups. TRACP 5a protein correlated significantly only with IgM-RF in RA. Among RA patients, mean TRACP 5a protein and IgM RF were significantly higher in nodule formers. In contrast, TRACP 5b activity was slightly elevated in RA and correlated with BALP, ICTP, and YKL-40 but not with IgM-RF or CRP. Mean TRACP 5b activity was no different in RA patients with or without nodules. TRACP isoforms could be useful disease markers in RA; TRACP 5a protein may be a measure of systemic inflammatory macrophage burden and disease severity. TRACP 5b activity is a marker for osteoclast number and perhaps local or systemic bone destruction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410226     DOI: 10.1359/jbmr.080329

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

1.  Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.

Authors:  Shinichiro Kuroshima; Virginia-Arlene A Go; Junro Yamashita
Journal:  Endocrinology       Date:  2011-11-22       Impact factor: 4.736

2.  Catabolic and anabolic periarticular bone changes in patients with rheumatoid arthritis: a computed tomography study on the role of age, disease duration and bone markers.

Authors:  Sophie Aschenberg; Stephanie Finzel; Sarah Schmidt; Sebastian Kraus; Klaus Engelke; Matthias Englbrecht; Jürgen Rech; Georg Schett
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

3.  Attenuation of adjuvant-induced arthritis by dietary sesamol via modulation of inflammatory mediators, extracellular matrix degrading enzymes and antioxidant status.

Authors:  Mahadevappa Hemshekhar; Ram Mohan Thushara; Sadashivaiah Jnaneshwari; Sannaningaiah Devaraja; Kempaiah Kemparaju; Kesturu Subbaiah Girish
Journal:  Eur J Nutr       Date:  2012-12-27       Impact factor: 5.614

4.  Monocytic MDSCs skew Th17 cells toward a pro-osteoclastogenic phenotype and potentiate bone erosion in rheumatoid arthritis.

Authors:  Shixian Chen; Chunqing Guo; Ran Wang; Zhitao Feng; Zheng Liu; Lisheng Wu; Di Zhao; Songyuan Zheng; Feilong Chen; Dingding Zhang; Juan Xu; Junqing Zhu; Xiaoguang Chen; Zhanguo Li; Christopher M Wise; Juan Li; Xiang-Yang Wang
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

Review 5.  Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.

Authors:  Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen
Journal:  Arthritis Res Ther       Date:  2011-04-28       Impact factor: 5.156

6.  Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature.

Authors:  Tracy A Briggs; Gillian I Rice; Sarah Daly; Jill Urquhart; Hannah Gornall; Brigitte Bader-Meunier; Kannan Baskar; Shankar Baskar; Veronique Baudouin; Michael W Beresford; Graeme C M Black; Rebecca J Dearman; Francis de Zegher; Emily S Foster; Camille Francès; Alison R Hayman; Emma Hilton; Chantal Job-Deslandre; Muralidhar L Kulkarni; Martine Le Merrer; Agnes Linglart; Simon C Lovell; Kathrin Maurer; Lucile Musset; Vincent Navarro; Capucine Picard; Anne Puel; Frederic Rieux-Laucat; Chaim M Roifman; Sabine Scholl-Bürgi; Nigel Smith; Marcin Szynkiewicz; Alice Wiedeman; Carine Wouters; Leo A H Zeef; Jean-Laurent Casanova; Keith B Elkon; Anthony Janckila; Pierre Lebon; Yanick J Crow
Journal:  Nat Genet       Date:  2011-01-09       Impact factor: 38.330

7.  Increased amount of phosphorylated proinflammatory osteopontin in rheumatoid arthritis synovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio.

Authors:  Jani Luukkonen; Laia Mira Pascual; Christina Patlaka; Pernilla Lång; Sanna Turunen; Jussi Halleen; Tomi Nousiainen; Maarit Valkealahti; Juha Tuukkanen; Göran Andersson; Petri Lehenkari
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

8.  Biosynthesis of gold nanoparticles for the treatment of osteoarthritis alone or in combination with Diacerein® in a rat model.

Authors:  Manal A Abdel-Aziz; Helmy M S Ahmed; Aziza A El-Nekeety; Hafiza A Sharaf; Sekena H Abdel-Aziem; Mosaad A Abdel-Wahhab
Journal:  Inflammopharmacology       Date:  2021-06-11       Impact factor: 4.473

9.  Association of Tartrate-Resistant Acid Phosphatase-Expressed Macrophages and Metastatic Breast Cancer Progression.

Authors:  Yu-Guang Chen; Anthony Janckila; Tsu-Yi Chao; Ren-Hua Yeh; Hong-Wei Gao; Su-Huei Lee; Jyh-Cherng Yu; Guo-Shiou Liao; Ming-Shen Dai
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

10.  Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome.

Authors:  Yi-Jhih Huang; Tsai-Wang Huang; Tsu-Yi Chao; Yu-Shan Sun; Shyi-Jou Chen; Der-Ming Chu; Wei-Liang Chen; Li-Wei Wu
Journal:  Oncotarget       Date:  2017-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.